▎ Sɛribrolaysin Risach
Wetin na di risach bakgrɔn fɔ Cerebrolysin?
Fɔs Fɔstɛm Risach: Insay di fɔs pat pan di 20t sɛntinari, sayɛnsman dɛn bin bigin fɔ pe atɛnshɔn to di we aw sɔm spɛshal tin dɛn we de na di bren kin afɛkt di nerve sɛl dɛn. da tεm de, dεn bin no se difrεn bayoaktiv sכbstans dεm de na di bren, we de ple imכtant rol fכ gro, divεlכpmεnt, ripa, εn fכnshכnal mεntenans fכ di nεv sεl dεm.
dis fכs stכdi dεm lay di tiori fawndeshכn fכ di sכbsכktiv risεch εn divεlכpmεnt fכ sεribrolaysin, we mek risechכr dεm fכ tray fכ εkstrakt εn aylכt bayoaktiv kכmכpכnt dεm frכm di bren tisu dεm fכ trit di nεv sεstem sik dεm.
Divεlכpmεnt fכ Ekstrakshכn Tεknכlכji: Wit di kכntinyu fכ progrεs fכ bayokεmistri εn mכlikul bayoloji tεknכlכji, risecharch dεm gεt mכr advans we fכ εkstrakt εn klin bayoaktiv sכbstans dεm frכm di bren tisu dεm.
Frɔm di 1960s to di 1970s, sɔm risach tim dɛn bin saksesful fɔ pul kɔmpleks miksɔp frɔm animal bren tisu dɛn lɛk pig bren, we gɛt difrɛn amino asid dɛn, pεptida dɛn, ɛn ɔda bayɔaktiv kɔmpɔnɛnt dɛn. dis εkstrakt dεm sho sכm nyutrishכnal εn protεktiv ifekt dεm pan nεv sεl dεm insay animal εkspεriεns dεm εn kin mek di nεv sεl dεm gro εn rεpa.
Risach pan di kכmכshכn εn di mεkanism fכ akshכn: Afta di ia dεm we dεn dכn du risach, dεn dכn כndastand dip כndastandin fכ di kכmכshכn εn mεkanism fכ akshכn fכ sεribrolaysin. dεn fכnshכn se sεribrolaysin gεt difrεn nyurotransmitta prεkursכr dεm, nyurotrofik fכktכ dεm, εn כda bayoaktiv pεptida dεm. dis kכmכpכnt dεm kin kכros di bכdi-bren barεri εn go insay di bren tisu, akt pan di nεv sεl dεm, protεkt di mεtabolism fכ di nεv sεl dεm, protin sεntesis, εn di rilis fכ nyurotransmitta dεm, we de mek di nεv sεl dεm wok fayn εn ple wan protεktiv εn riparativ rol fכ di nεv sεl dεm we dεn dכn pwεl.
Eksplכreshכn כf Klinik Aplikεshכn: Bays pan in gud ifekt dεm na animal εkspεriεns, dεn dכn aplay sεribrolaysin sכmtεm fכ klinik risach. Fɔs, dɛn bin de yuz am mɔ fɔ trit sɔm nyurodijɛnɛraytiv sik dɛm na di nervɔs sistɛm, lɛk Alzaima sik, Pakinsin sik, ɛn di nerve function disorders we kin kam wit bren trauma, sɛribrovaskul sik dɛm, ɛn ɔda tin dɛm fɔ layf.
Wetin na di we aw Sɛribrolaysin de wok?
1. I gɛt nyuroprotɛktiv ifɛkt
Ridyus Hypoxik Damej: Insay in vitro mכdel dεm, lεk di PC12 sεl mכdel we dεn trit wit kכbalt klorayd (CoCl2), Sεribrolysin de sho nyuroprotεktiv ifekt [1] . spεshal wan, i de mεnten di dayamita fכ di PC12 sεl dεm we nכ difrεns afta CoCl2 tritmεnt, i de ridyus di sεl shrinkage; di dכn di aktvכti fכ pro-apoptotik Caspase in כndifrεns PC12 sεl dεm כnda CoCl2 strεs; rεstכr di mεtabolik aktiviti fכ di כndifrεns εn difrεnt PC12 sεl dεm we CoCl2 dεm dεm; εn di sem tεm de ridyus di supεrכksayd lεvεl we dεn obsכv afta CoCl2 εkspכzכn. i mεkanism fכ akshכn kin bi tru fכ inkrεs di fכsfכrayleshכn fכ GSK3β, we de inhεbit di aktvכti fכ GSK3β. dis kin gεt klinik signifyans fכ Alzaima sik, biכs di aktvכti fכ GSK3β de riliyt to di prodyushכn fכ amyloid β.
di rol we di Ischemic Stroke de ple: pan di sik pipul dεm we gεt ischemic stroke, Cerebrolysin kin ple nyuroprotektiv rol tru mכltipכl path dεm. Insay di fɔs klinik trayal dɛm, we dɛn de stɔdi di pipul dɛm we gɛt strok we nɔ gɛt bɛtɛ afɛkt, bikɔs ɔf di jɛnɛral gud prɔgnosis fɔ dis pipul dɛm, i kin gɛt ifɛkt pan flɔ ɔ siling, we kin mek nɔ klia difrɛns bitwin di tritmɛnt grup dɛm [2] . Bɔt, sabgrup analisis fɔ di pasɛnt dɛn we bin afɛkt mɔ bad bad wan sho se Sɛribrolaysin bin gɛt signifyant pɔsitiv ifɛkt fɔ ɛp fɔ mek dɛn wɛl, ɛn di magnitud fɔ in ifɛkt bin go ɔp wit di siriɔs we aw di strok bin de. Apat frɔm dat, dɛn kin jɔyn Sɛribrolaysin sef wan wit trombolaytik tɛrapi. i nכ nכ gεt nyuroprotεktiv ifekt bכt i gεt di pכtεnshal fכ nerv rεkכvεshכn εn i de sho efficacy pan pasεn dεm we gεt mכdarεt to siriכs strכk [2, 3]..
2. As wan ejen we de mek di nerv ripa
fכ protεkt kכmכnikεshכn bitwin nεv sεl dεm: sεribrolaysin na protin-bεys likwid miksכp we gεt 85% fri amino asid dεm εn 15% bayoaktiv lכw-mכlikul-weyt amino asid sikεns dεm, inklud lכw-mכlikul-weyt nyuropεptida dεm [4, 5] . dis aktiv bren nyuropεptida dεm kin go insay di bכdi-bren barεri εn nyuron dεm de yuz dεm fכ kכmyunikeshn wit dεn wan dεm.
ifekt pan Nyurodivεlכpmεnt Dizכrd dεm: Insay pikin nyurosaykyatri, dεn kin kכnsidr Sεribrolysin as pεptidargik sכbstans wit mכltimodal mεkanism fכ akshכn εn i de akt lεk nεv rεpa ejen. Insay di prɛvasiv divɛlɔpmɛnt dizayd (PDD) we inklud ɔtizm ɛn Asperger’s syndrome, wan nyu tritmɛnt we dɛn kin du wit injɛktabl Sɛribrolaysin as di men tritmɛnt kɔmpɔnɛnt sho se di ɔtistik kwaliti dɛn fɔ ɔl di pasɛnt dɛn we dɛn trit bin impɔtant ɛn ridyus bad bad wan, ɛn di men ɔtistik kwaliti dɛn fɔ sɔm pasɛnt dɛn bin dɔnawe wit ɛni sayd ɛfɛkt [5]..
3. Tεrapi ifekt pan post-strok spasm
Improving Spasm-related Indicators: Tru di stכdi we dεn du pan wan 56 ia ol pasεnshכn we gεt krεse strכk, dεn injεkt Sεribrolysin intramכskul insay di spastik limb pan wan doz we na 10 mL pan de fכ 30 dez. Afta tritmɛnt, di autkam indikɛtɔ dɛm we gɛt fɔ du wit spasm lɛk di Manual Muscle Test (MMT) impruv bay 70%, ɛn di Modified Ashworth Scale (MAS) dכn dכn bay 2 poɛnt [6] . Di pasɛnt bin ripɔt bak di bɛnifit ifɛkt dɛn pan di mud ɛn motiveshɔn.
4. Impekt pan liva injuri
Improving Liver Injury Indicators: Insay di wan dɛn we gɛt sik dɛn we nɔ de mɛn, di tritmɛnt fɔ di akyu tin dɛn we kin mek pɔsin in layf de pan denja kin kɔmpleks. Fɔ di wan dɛn we gɛt strok we dɛn trit wit Cerebrolysin, if aspartate aminotransferase (AST) ɛn/ɔ alanine aminotransferase (ALT) inkris de, klinik stɔdi dɛn dɔn sho se Cerebrolysin kin impruv di AST lɛvɛl fɔ bɔku pan di wan dɛn we gɛt strok we gɛt liva injuri [7]..
Rivεs di Inhibishכn fכ Nyurojεnεsis: Insay wan maws mכdel fכ nכn-alkoholik fεt liva sik (NAFLD), bay we dεn evaluate di bihayvכral εn histכlכjik autkam, dεn fכnshכn se Sεribrolysin kin rivεs di bihayvya lεk anxiety bכt i fεl fכ impruv sכt tεm mεmכri כ rεsכv sεl proliferashכn na di hipokampus afta MCD it intake [7].
Wetin na di aplikeshɔn dɛm fɔ Cerebrolysin?
Aplikeshɔn dɛn na Pikin Nyurosaykayatri:
Fɔ Mek di Nɛv Sɛl dɛn Gɛt: Insay 1949, wan sayɛnsman we nem Gɛhart Hara we kɔmɔt na di Yunivasiti ɔf Innsbruk insay Ɔstria bin ripɔt se Sɛribrolaysin, we na wan prɔtin wata we di ɛnzaymatik haydrolisis na di bren tisu kin mek, kin mek di nɛv sɛl dɛn wok. sεribrolaysin na protin-bεys likwid miksכp we kכmכp fכ 85% fri amino asid dεm εn 15% bayoaktiv lכw mכlikul-weyt amino asid sikεns dεm, inklud lכw mכlikul-weyt nyuropεptida dεm. dis nyuropεptida dεm inklud nyurotrofik fכktכ we kכmכt na di bren, nyurotrofik fכktכ we kכmכt na di glial sεl layn, nyurotrofik fכktכ we de kכmכt na di nεv, εn di ciliary nyurotrofik fכktכ [4]..
mכltimodal mεkanism fכ akshכn: dεn kin kכnsidr sεribכlaysin as pεptida sכbstans wit mכltimodal mεkanism fכ akshכn. di aktv bren nyuropεptida dεm we i gεt kin go insay di bכdi-bren barεri εn nyuron dεm de yuz dεm fכ kכmyunikeshn wit dεn wan dεm. I sef, tolerabiliti, ɛn ɛfifishins dɔn establish insay ɛkspirimɛnt stɔdi ɛn klinik trial. sεribralaysin de sho se i rili wayd di tεm we di tεm we dεn de tεrapi εn dεn kin yus am as nyuroprotεktiv εn nyurotrofik ejen, we de εp fכ delay di prכgreshכn fכ di bren sik dεm [4]..
Di we aw dɛn kin yuz am fɔ trit pɔsin we gɛt strok:
Ifekt pan di pesin dɛm we gɛt difrɛn kayn sik: Insay strok tritmɛnt, dɛn bin de du di fɔs klinik trial dɛm mɔ pan di pipul dɛm we gɛt strok we nɔ bin afɛkt bɛtɛ, we kin gɛt gud prɔgnosis. Bɔt bikɔs ɔf dis sɛlɛkshɔn, i kin gɛt ifɛkt pan flɔ ɔ siling na di rikavari mɛsej fɔ mild kes dɛm, we kin mek i nɔ izi fɔ sho klia bɛnifit bitwin di tritmɛnt grup dɛm. difrεnt frכm dat, sabgrכp analisis fכ mכr siriכs afekt pasεnshכn sho se Cerebrolysin bin gεt signifyant pכsitiv ifekt pan εnhans rεkכvεshכn. bay di rizulyt dεm fכ mכltipכl stכdi dεm, i klia se di magnitכd fכ di ifekt fכ Sεribrolysin de inkrεs wit di siriכs fכ di strכk [2]..
Kɔmbayn Yuz wit Thrombolytic Therapy: Ɔda kɔntrol stɔdi dɛn dɔn sho se dɛn kin jɔyn Cerebrolysin sef wan wit thrombolytic therapy. Dis biεn tεm, dεn nכ tεst di Cerebrolysin nכto כnli fכ in nyuroprotεktiv ifekt bכt fכ in nεv rεkכvεshכn pכtεnshal εn dεn sho efyushכn pan pasεn dεm we gεt mכdarεt to siriכs strכk [2]..
Efεkt pan Fכnshכnal Rεkכvεshכn: Sεribrolaysin dεn sho bεnεfit pan pasεn dεm we gεt mכdarεt to siriכs ischemic strok. we dεn yuz am in kכmbaynshכn wit nyurorihabiliteshכn kכmpεr wit nyurorihabiliteshכn nכmכ, i gεt jεnarali signifyant ifekt pan fכnshכnal rεkכvεshכn. Dis de gi dairekshɔn fɔ mɔ strɔng risach dizayn dɛn tumara bambay.
Aplikeshɔn fɔ di Tritmɛnt fɔ Akyu Ischemic Stroke:
Impekt pan Mɔtaliti ɛn Advays Ivint: Mɔdaret-kwaliti pruf sho se Sɛribrolysin kin gɛt smɔl bɛnifit ifɛkt fɔ mek dɛn nɔ day ɔl-kɔz ɔ di totɛl nɔmba fɔ siriɔs bad bad tin dɛn we kin apin na akyu ischemic strok. pan di sem tεm, mכdarεt-kwaliti pruf dεn sho bak se we dεn yus Sεribrolysin kin inkrεs di כkכrεshכn fכ nכn-fatal siriכs advεs ivent dεm [8] . sכm spεshal, insay di sכbgrכp wit dכz 30 mL fכ 10 dez (kumulativ dכz fכ 300 mL), di inkrεs pan nכn-fatal siriכs advεs ivent dεm bin mכr sכmtin [8]..
Impekt pan Ɔda Indikɛtɔ dɛm: Nɔn pan di trayal dɛm we dɛn put insay nɔ ripɔt bad bad fɛnshɔnal autkam dɛm we dɛn difayn as day ɔ dipɛnsin na di ɛnd ɔf di fɔlɔp tɛm, day kwik (insay tu wik afta strok bigin), tɛm fɔ go bak na wok kapasiti, ɛn kwaliti ɔf layf ɛn ɔda indikɛtɔ dɛm. Na wan trayal nɔmɔ bin ripɔt klia wan di tin dɛn we kin mek pɔsin day, lɛk di sɛribra infarkshɔn, at pwɛl, pulmonari ɛmbolizm, ɛn nyumonia, ɛn ɔda tin dɛn, bɔt smɔl difrɛns nɔ bin de pan di distribyushɔn bitwin di Sɛribralaysin grup ɛn di plesibo grup [8]..
Aplikeshɔn dɛm fɔ di Tritmɛnt fɔ Kɔgnitiv Impairment:
Improving Cognitive Function and Delaying Progression: Kɔgnitiv impairment na wan pan di impɔtant tin dɛm we de apin na di mɔdan wɛlbɔdi biznɛs. Naw, i pas 55 milyɔn pipul dɛm ɔlsay na di wɔl wae gɛt dis maynia sik. Dimɛnshɔn na wan pan di men tin dɛm wae kin mek pipul dɛm wae dɔn ol na di wɔl gɛt disabled ɛn de dipɛnshɔn. Mɔr pasɛnt wae gɛt smɔl smɔl kɔgnitiv impairment kin gɛt bɔrku risk fɔ go bifo to dis maynia sik wae yu kɔmpia am wit dɛn kɔmpin dɛm. Bikɔs ɔf di impak we COVID-19 gɛt, di nɔmba fɔ pipul dɛn we gɛt prɔblɛm wit dɛn maynd dɔn bɔku bak. Sεribrolaysin na dכg we nכ kin כnli impruv di kכgnitiv fכnshכn bכt i kin slo dכn in prכgreshshכn [9]..
Aplikeshɔn fɔ Pasɛnt dɛn we gɛt Kɔnshɛns Disɔda afta Strɔk:
Improving di Level of Consciousness: Wan retrospektiv stכdi sho se Cerebrolysin kin impruv di lεvεl fכ kכnsεns fכ di sik pipul dεm we de na minimal kכnsεns stet afta strok. Insay dis stכdi, dεn bin stכdi di pasεnshכn dεm we de na minimal kכnsεshכn stet afta ischemic εn/כ hεmorajik strok, εn dεn bin evaluate dεn pasεnshכn ya akɔdin to di Rivays Kɔma Rεkכvri Skel (CRS-R). Ɔl di pasɛnt dɛn bin gɛt kɔmprɛhnsiv rihabiliteshɔn tritmɛnt inklud fizik tɛrapi ɛn ɔkupeshɔn tɛrapi. Dɛn kɔmpia di pasɛnt dɛn we bin gɛt Cerebrolysin tritmɛnt wit di wan dɛn we nɔ bin gɛt Cerebrolysin tritmɛnt. di risalts sho se afta dεn adjכst fכ kכnfyus fכktכ dεm, di Cerebrolysin tritmεnt grup bin gεt sכm improvεmεnt in di CRS-R skכ, spεshal wan in di כral mכtal εn arousal sכbskayl [10]..
Aplikeshɔn fɔ Pasɛnt dɛn we gɛt Liva Injuri:
Di tritmɛnt we dɛn kin gɛt pan di wan dɛn we gɛt liva injuri: Fɔ di wan dɛn we gɛt sik dɛn we nɔ de mɛn, di tritmɛnt fɔ akyu tin dɛn we kin mek dɛn layf de pan denja na prɔblɛm bikɔs dɔktɔ dɛn nid fɔ tink bɔt di ifɛkt dɛn we di mɛrɛsin dɛn we gɛt bɔku bɔku sistɛm dɛn kin gɛt. Fɔ tɔk bɔt Cerebrolysin, as amplifaya fɔ di Sonic Hedgehog signaling pathway ɛn wan pan di smɔl apruv nyurotrofik tɛrapi drɔgs fɔ strok pasɛnt, kɔnsyus de se if dɛn aktiv di Hedgehog pathway pasmak kin mek di nɔ-alcoholic fatty liver disease (NAFLD) go bifo to sirosis. i dכn fכnshכn se Cerebrolysin klinikli impruv di aspartate aminotransferase (AST) lεvεl dεm fכ mכst strok pasεnshכn dεm wit liva injuri. insay di εkspεriεns sεtin, Cerebrolysin bin ebul fכ rivεs di bihayvya lεk anxiety in wan maws mכdel fכ nכn-alkohol fεt liva sik bכt i nכ impruv sכt tεm mεmכri כ rεsכk sεl proliferashכn na di hipokampus afta MCD it intake [7]..
fכ kכnklud, sεribrolaysin kin mek di nεv sεl dεm ripa εn rigεnεreshכn, rεgεl di bεlε fכ di nyurotransmit dεm fכ impruv signal transmishכn, gi nyutriεnt fכ di nεv sεl dεm εn i kin mek dεn tכlerans fכ damej, εn i kin mek di nεv dεm bak. Klinik wan, dεn kin yus sεribralaysin bכku bכku wan fכ trit difrεn nεv sεstem sik dεm lεk bren trauma εn sεkyula fכ sεribrovaskul sik dεm, we kin impruv di sik pipul dεm in simptom dεm εn kwaliti כf layf. pan di sem tεm, i na imכtant tul bak na nyurosayns risach, we de εp fכ gεt dip כndastandin fכ di fysiolojikal fכnshכn dεm fכ di nεv sεl dεm εn di mεkanism dεm fכ divεlכpmεnt εn ripεr di nεv sistεm, i de gi tiori εn aydia fכ divεlכpmεnt fכ nyu nyuroprotεktiv εn rεpa drog dεm, εn i gεt bכku minin pan di fil dεm fכ di nεv sistεm sik tritmεnt εn nyurosayns risεch.
Bɔt di pɔsin we rayt di buk
Di tin dɛn we wi dɔn tɔk bɔt ɔp, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.
Sayɛns Jɔnal Author
Ziganshina LE na wan risachman we gɛt fɔ du wit sɔm notabɛl institiushɔn dɛn. Dɛn tin ya na di Rɔshian Mɛdikal Akademi fɔ Kɔntinyu Prɔfɛshɔnal Ɛdyukeshɔn (RMANPO), Pipul dɛn Friɛndship Yunivasiti na Rɔshia, Kazan Stet Mɛdikal Yunivasiti, Rɔshian Mɛdikal Akademi fɔ Kɔntinyu Prɔfɛshɔnal Ɛdyukeshɔn, Ministri fɔ Wɛlbɔdi fɔ di Rɔshian Fɛdareshɔn, Kɔkrin Rɔshia, Kazan Fɛdaral Yunivasiti, Ministri fɔ Wɛlbɔdi fɔ di Ripɔblik fɔ Tatarstan, Kazan Stet Mɛdikal Akademi, ɛn S. V. Kurashov Med Inst. In institiushɔnal kɔnekshɔn dɛn de sho se i gɛt strɔng bakgrɔn pan mɛdikal ɛn wɛlbɔdi sayɛns.
In risach intres dɛn de akɔdin to difrɛn sɔbjɛkt kategori dɛn. I gɛt ɛkspɛriɛns pan Jɛnɛral & Intanɛt Mɛdisin, Famakɔlɔji & Famasi, Pɔblik, Envayrɔmɛnt & Ɔkupeshɔn Ɛlth, Nyurosayns & Nyurɔlɔji, ɛn Risach & Ɛkspirimɛnt Mɛdisin. Di wok we i de du pan dɛn tin ya de sho di bɔku tin dɛn we i no ɛn di tin dɛn we i dɔn du fɔ mek di mɛdikal sayɛns ɛn wɛlbɔdi biznɛs go bifo. Ziganshina LE de list in di rεfrεns כf saytεshכn [8].
